Comparing the longer regimen and the shorter regimen for multidrug-resistant pulmonary tuberculosis patients treated under the programmatic management of drug-resistant tuberculosis.

UNLABELLED

Multidrug-resistant tuberculosis is a major public health concern with prolonged infectivity, a complex treatment regimen, and lower treatment success rates. Despite the significant progress made by India in the control of Tuberculosis, it remains the second leading cause of mortality among infectious diseases. Shorter treatment courses for multidrug-resistant tuberculosis (MDR-TB) can enhance patient adherence by decreasing the length of time for medication intake and alleviating the challenges associated with prolonged treatment. Evaluating the effectiveness of various treatment regimens is crucial for identifying the best balance among treatment duration, efficacy, adverse drug effects, and patient adherence. A prospective, observational study on 50 MDR-TB patients was carried out at a tertiary care hospital. The final cure rates were 88% in the shorter regimen and 84% in the longer regimen, with 12% treatment failure in both groups. Both shorter and longer regimens demonstrated comparable efficacy with slightly better adherence in the shorter regimen.

CLINICAL TRIAL REGISTRATION

The study was registered in the Clinical Trials Registry-India (Indian Council of Medical Research-National Institute of Medical Statistics), https://ctri.nic.in/, CTRI registration number CTRI/2024/01/061453, registration date 15/1/2024, date of first enrollment is 24/1/2024.